

Dr Farah Al-Beidh
Clinical Trial Manager
Imperial College London / ICNARC
Tel: 020 7831 6878
Mobile: 07714051401
Fax: 020 7831 6879
Email: ukremap-cap@icnarc.org

17/09/21

Re: Study Title: Randomized, Embedded, Multi-factorial, Adaptive Platform Trial for community - Acquired Pneumonia

REC reference: 18/lo/0660

EudraCT number: 2015-002340-14

IRAS project ID: 237150

Non Substantial amendment 04 (NSA04) Expedited Approval

I am submitting non-substantial amendment 04 for the REMAP-CAP study.

This involves clarification that the current funding allows for continued REMAP-CAP recruitment till the 30th June 2022.

Updated end date for patient recruitment. REMAP-CAP is designed as a perpetual study but additional funding extensions (provided by the RECOVER agreement and the NIHR) are now in place to continue recruitment of REMAP-CAP patients till 30.06.22

Many Thanks

Farah

Farah Al-Beidh PhD

UK REMAP-CAP Trial Manager

Imperial College London / ICNARC

Tel: 020 7831 6878

Mobile: 07714051401

Fax: 020 7831 6879

Email: ukremap-cap@icnarc.org

Coordinating Centers

EUROPE

University Medical Center Utrecht
Heidelberglaan 100
3584 CX

THE NETHERLANDS

Phone +31 (0) 6 277 444 77
Email prepare_icu@umcmrecht.nl

NEW ZEALAND

The Medical Research Institute of
New Zealand
Private Bag 7902, Newtown,
Wellington 6242,
NEW ZEALAND
Phone +64 4 805 0147
Email anne.turner@mrnz.ac.nz

AUSTRALIA

The Australian and New Zealand
Intensive Care Research Centre,
Monash University
Level 3, 533 St Kilda Road
Melbourne, Victoria, 3004
AUSTRALIA
Phone +61 3 9903 0247
Email anzirc@med.monash.edu